Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis.

PURPOSE To evaluate the effect of antifungal prophylaxis on all-cause mortality as primary outcome, invasive fungal infections (IFIs), and adverse events. Many studies have evaluated the role of antifungal prophylaxis in cancer patients, with inconsistent conclusions. METHODS We performed a systematic review and meta-analysis of randomized, controlled trials comparing systemic antifungals with placebo, no intervention, or other antifungal agents for prophylaxis in cancer patients after chemotherapy. The Cochrane Library, MEDLINE, conference proceedings, and references were searched. Two reviewers independently appraised the quality of trials and extracted data. RESULTS Sixty-four trials met inclusion criteria. Antifungal prophylaxis decreased all-cause mortality significantly at end of follow-up compared with placebo, no treatment, or nonsystemic antifungals (relative risk [RR], 0.84; 95% CI, 0.74 to 0.95). In allogeneic hematopoietic stem-cell transplantation (HSCT) recipients, prophylaxis reduced all-cause mortality (RR, 0.62; 95% CI, 0.45 to 0.85), fungal-related mortality, and documented IFI. In acute leukemia patients, there was a significant reduction in fungal-related mortality and documented IFI, whereas the difference in mortality was only borderline significant (RR, 0.88; 95% CI, 0.74 to 1.06). Prophylaxis with itraconazole suspension reduced documented IFI when compared with fluconazole, with no difference in survival, and at the cost of more adverse events. On the basis of two studies, posaconazole prophylaxis reduced all-cause mortality (RR, 0.74; 95% CI, 0.56 to 0.98), fungal-related mortality, and IFI when compared with fluconazole. CONCLUSION Antifungal prophylaxis decreases all-cause mortality significantly in patients after chemotherapy. Antifungal prophylaxis should be administered to patients undergoing allogeneic HSCT, and should probably be administered to high-risk acute leukemia patients.

[1]  L. Leibovici,et al.  Empirical antifungal therapy for patients with neutropenia and persistent fever: Systematic review and meta-analysis. , 2008, European journal of cancer.

[2]  J. Maertens.  Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies , 2007, European journal of haematology.

[3]  J. Perfect,et al.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.

[4]  J. Lipton,et al.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. , 2007, The New England journal of medicine.

[5]  A. Glasmacher,et al.  Current experience with itraconazole in neutropenic patients: a concise overview of pharmacological properties and use in prophylactic and empirical antifungal therapy , 2006 .

[6]  Peter G. Pappas,et al.  Invasive Fungal Pathogens: Current Epidemiological Trends , 2006 .

[7]  E. Thiel,et al.  Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  A. Gorelik,et al.  A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients , 2006, Bone Marrow Transplantation.

[9]  S. Elad,et al.  Oral candidiasis prevention in transplantation patients: a comparative study , 2006, Clinical transplantation.

[10]  J. Perfect,et al.  Non‐comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation , 2006, Transplant infectious disease : an official journal of the Transplantation Society.

[11]  D. Benjamin,et al.  Safety and Pharmacokinetics of Intravenous Anidulafungin in Children with Neutropenia at High Risk for Invasive Fungal Infections , 2006, Antimicrobial Agents and Chemotherapy.

[12]  A. Glasmacher,et al.  An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. , 2006, The Journal of antimicrobial chemotherapy.

[13]  P. Gøtzsche,et al.  Voriconazole versus amphotericin B in cancer patients with neutropenia. , 2006, The Cochrane database of systematic reviews.

[14]  C. Viscoli,et al.  Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin , 2006, British journal of haematology.

[15]  E. Estey,et al.  Open-Label, Randomized Comparison of Itraconazole versus Caspofungin for Prophylaxis in Patients with Hematologic Malignancies , 2006, Antimicrobial Agents and Chemotherapy.

[16]  A. Glasmacher,et al.  Caspofungin treatment in severely ill, immunocompromised patients: a case-documentation study of 118 patients. , 2006, The Journal of antimicrobial chemotherapy.

[17]  M. Falagas,et al.  Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta‐analysis of randomised‐controlled trials , 2005, British journal of haematology.

[18]  N. Chao,et al.  Pharmacokinetic and Maximum Tolerated Dose Study of Micafungin in Combination with Fluconazole versus Fluconazole Alone for Prophylaxis of Fungal Infections in Adult Patients Undergoing a Bone Marrow or Peripheral Stem Cell Transplant , 2005, Antimicrobial Agents and Chemotherapy.

[19]  W. Sluiter,et al.  Tolerance and efficacy of amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients , 1997, European Journal of Clinical Microbiology and Infectious Diseases.

[20]  J. Ninane,et al.  A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies , 1994, European Journal of Clinical Microbiology and Infectious Diseases.

[21]  M. Kalin,et al.  Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients , 2005, European Journal of Clinical Microbiology and Infectious Diseases.

[22]  E. Estey,et al.  Intravenous Voriconazole (IV-VORI) Prevents Invasive Fungal Infections (IFI) in Patients (pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS). , 2004 .

[23]  N. Callander,et al.  Efficacy of Fluconazole Prophylaxis for Autologous Peripheral Blood Stem Cell Transplantation: Results of a Prospective, Randomized, Controlled, Multicenter, Open Label Study. , 2004 .

[24]  J. Lipton,et al.  Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  J. Wingard.  Design issues in a prospective randomized double-blinded trial of prophylaxis with fluconazole versus voriconazole after allogeneic hematopoietic cell transplantation. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  J. Szer,et al.  A pilot study of targeted itraconazole prophylaxis in patients with graft-versus-host disease at high risk of invasive mould infections following allogeneic stem cell transplantation , 2004, Bone Marrow Transplantation.

[27]  J. Epstein,et al.  Topical polyene antifungals in hematopoietic cell transplant patients: tolerability and efficacy , 2004, Supportive Care in Cancer.

[28]  W. Leisenring,et al.  Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. , 2004, Blood.

[29]  H. Kantarjian,et al.  Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy , 2004, Cancer.

[30]  A. Gratwohl,et al.  Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients , 1995, Supportive Care in Cancer.

[31]  J. Mardiak,et al.  Fluconazol plus ofloxacin in prophylaxis of infections in patients with acute leukemia: a comparative study , 1993, Supportive Care in Cancer.

[32]  B. Djulbegovic,et al.  Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[34]  H. Ulmer,et al.  Fungal colonization in neutropenic patients: a randomized study comparing itraconazole solution and amphotericin B solution , 2003, Annals of Hematology.

[35]  M. Territo,et al.  Intravenous and Oral Itraconazole versus Intravenous and Oral Fluconazole for Long-Term Antifungal Prophylaxis in Allogeneic Hematopoietic Stem-Cell Transplant Recipients: A Multicenter, Randomized Trial , 2003, Annals of Internal Medicine.

[36]  Yu Shen,et al.  Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction , 2003, Cancer.

[37]  C. Beyan,et al.  Itraconazole is not effective for the prophylaxis of fungal infections in patients with neutropenia , 2003, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[38]  M. Asaka,et al.  [Effect of prophylaxis against myocosis in patients with hematological malignancy disease: efficacy of dosage of itraconazole]. , 2003, The Japanese journal of antibiotics.

[39]  S. D. Mitrokhin.  [Itraconazole (Orungal) in the treatment of mycotic infections in oncologic patients]. , 2003, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic].

[40]  S. Fook-Chong,et al.  Randomized trial of fluconazole versus low‐dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation , 2002, American journal of hematology.

[41]  Richard Sylvester,et al.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.

[42]  E. Bow,et al.  Antifungal prophylaxis for severely neutropenic chemotherapy recipients , 2002, Cancer.

[43]  J. L. Goodman,et al.  Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy. , 2002, The American journal of medicine.

[44]  T. Calandra,et al.  Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer , 2002 .

[45]  D. Denning,et al.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  H. Jürgens,et al.  Liposomal amphotericin B for prophylaxis of invasive fungal infections in high‐risk paediatric patients with chemotherapy‐related neutropenia: interim analysis of a prospective study , 2001, Mycoses.

[47]  K. Vandewoude,et al.  Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients. , 2001, The Journal of antimicrobial chemotherapy.

[48]  J. Levron,et al.  Pharmacokinetics of Itraconazole Oral Solution in Neutropenic Children during Long-Term Prophylaxis , 2001, Antimicrobial Agents and Chemotherapy.

[49]  S J Lin,et al.  Aspergillosis case-fatality rate: systematic review of the literature. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[50]  E. Bow,et al.  Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. The Canadian Fluconazole Study. , 2000, The Journal of antimicrobial chemotherapy.

[51]  A. Elmaagacli,et al.  Fungal colonization and invasive fungal infections following allogeneic BMT using metronidazole, ciprofloxacin and fluconazole or ciprofloxacin and fluconazole as intestinal decontamination , 2000, Bone Marrow Transplantation.

[52]  Y. Kanda,et al.  Prophylactic action of oral fluconazole against fungal infection in neutropenic patients , 2000, Cancer.

[53]  H. Prentice,et al.  Towards a targeted, risk‐based, antifungal strategy in neutropenic patients , 2000, British journal of haematology.

[54]  J. Harousseau,et al.  Itraconazole Oral Solution for Primary Prophylaxis of Fungal Infections in Patients with Hematological Malignancy and Profound Neutropenia: a Randomized, Double-Blind, Double-Placebo, Multicenter Trial Comparing Itraconazole and Amphotericin B , 2000, Antimicrobial Agents and Chemotherapy.

[55]  A. Ganser,et al.  Intensive Intravenous Amphotericin B for Prophylaxis of Systemic Fungal Infections , 2000, Chemotherapy.

[56]  D. Touw,et al.  Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial , 2000, Bone Marrow Transplantation.

[57]  R. Collins,et al.  Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group , 2000, Bone Marrow Transplantation.

[58]  M. Nucci,et al.  A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[59]  T. Sauerbruch,et al.  Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl‐β‐cyclodextrin oral solution or coated‐pellet capsules , 1999, Mycoses.

[60]  S. Durrant,et al.  A double-blind comparison of fluconazole and nystatin in the prevention of candidiasis in patients with leukaemia , 1999 .

[61]  W. Siegert,et al.  Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. , 1999, Blood.

[62]  H. van Tinteren,et al.  Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology. , 1999, Journal of clinical pathology.

[63]  E. Bow,et al.  Randomized Placebo-Controlled Trial of Fluconazole Prophylaxis for Neutropenic Cancer Patients: Benefit Based on Purpose and Intensity of Cytotoxic Therapy , 1999 .

[64]  A. Favero,et al.  Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[65]  M. Okada,et al.  Fluconazole versus amphotericin B for the prevention of fungal infection in neutropenic patients with hematologic malignancy. , 1999, Drugs under experimental and clinical research.

[66]  E. Spasov,et al.  Antifungal prophylaxis with low doses fluconazole in patients with hematological malignancies. , 1999, Folia medica.

[67]  H. Prentice,et al.  A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group. , 1999, British journal of haematology.

[68]  S. McCann,et al.  Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study , 1999, Bone Marrow Transplantation.

[69]  R. Mücke,et al.  Fluconazole prophylaxis in patients with head and neck tumours undergoing radiation and radiochemotherapy , 1998, Mycoses.

[70]  W. Hiddemann,et al.  Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia , 1998, Cancer.

[71]  W. Leisenring,et al.  The Effect of Prophylactic Fluconazole on the Clinical Spectrum of Fungal Diseases in Bone Marrow Transplant Recipients with Special Attention to Hepatic Candidiasis: An Autopsy Study of 355 Patients , 1998, Medicine.

[72]  C. Jacquelinet,et al.  Prophylactic use of itraconazole for the prevention of invasive pulmonary aspergillosis in high risk neutropenic patients. , 1998, Leukemia & lymphoma.

[73]  B. Kornhuber,et al.  Fluconazole versus nystatin in the prevention of candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer. , 1997, The Journal of antimicrobial chemotherapy.

[74]  S D Walter,et al.  The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. , 1997, Journal of clinical epidemiology.

[75]  P. Gøtzsche,et al.  Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia , 1997, BMJ.

[76]  N. Kröger,et al.  Antimycotic therapy with liposomal amphotericin-B for patients undergoing bone marrow or peripheral blood stem cell transplantation. , 1997, Leukemia and Lymphoma.

[77]  L. Bergmann,et al.  Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies. , 1996, The Journal of antimicrobial chemotherapy.

[78]  G. Ehninger,et al.  Fluconazole in the prophylaxis of fungal infection after bone marrow transplantation , 1996, Mycoses.

[79]  A. Prentice,et al.  Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia. , 1995, The Journal of antimicrobial chemotherapy.

[80]  A. Schaffner,et al.  Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. , 1995, The Journal of infectious diseases.

[81]  B. Hirschel,et al.  Antifungal Prophylaxis in Severely Neutropenic Patients: How Much Fluconazole is Necessary? , 1995, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[82]  M. Levenstein,et al.  Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. , 1995, The Journal of infectious diseases.

[83]  R. Haznedar,et al.  Prophylactic use of fluconazole in neutropenic cancer patients. , 1995, Postgraduate medical journal.

[84]  M. Kalin,et al.  Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever--preliminary observations from a pilot, exploratory study. , 1995, The Journal of infection.

[85]  A. Ibatici,et al.  Efficacy of different prophylactic antifungal regimens in bone marrow transplantation. , 1995, Haematologica.

[86]  J. Esteve,et al.  [Intravenous amphotericin B as prevention of deep mycoses in allogeneic bone marrow transplantation]. , 1994, Medicina clínica (Ed. impresa).

[87]  P. Beatty,et al.  The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. , 1994, The American journal of medicine.

[88]  C. Begg,et al.  Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.

[89]  T. Barbui,et al.  Preventing Fungal Infection in Neutropenic Patients with Acute Leukemia: Fluconazole Compared with Oral Amphotericin B , 1994, Annals of Internal Medicine.

[90]  F. Baillie,et al.  The effect of fluconazole as prophylaxis for neutropenic patients on the isolation of Candida spp. from surveillance cultures. , 1994, The Journal of antimicrobial chemotherapy.

[91]  O. Ringdén,et al.  Fungal prophylaxis with AmBisome in liver and bone marrow transplant recipients: results of two randomized double-blind studies. , 1994, Transplantation proceedings.

[92]  E. Anaissie,et al.  Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B , 1994, Cancer.

[93]  H. Sakamaki,et al.  Prevention of invasive fungal infection during chemotherapy-induced neutropenia in patients with acute leukemia. , 1994, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases.

[94]  P. Chandrasekar,et al.  Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic cancer patients. Bone Marrow Transplantation Team. , 1994, Chemotherapy.

[95]  P. Chandrasekar,et al.  The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients. Bone Marrow Transplantation Team. , 1994, The Journal of antimicrobial chemotherapy.

[96]  A. Goldstone,et al.  Early AmBisome in febrile neutropenia in patients with haematological disorders. , 1994, Bone marrow transplantation.

[97]  P. Ljungman,et al.  Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. , 1993, Bone marrow transplantation.

[98]  H. Sakamaki,et al.  Fluconazole versus oral amphotericin B in preventing fungal infection in chemotherapy‐induced neutropenic patients with haematological malignancies Vergleichende Studie über , 1993, Mycoses.

[99]  T. Yamada,et al.  Prevention of bacterial and fungal infections in acute leukemia patients: a new and potent combination of oral norfloxacin and amphotericin B. , 1993, Internal medicine.

[100]  J. Trupl,et al.  Fluconazole in children: first experience with prophylaxis in chemotherapy-induced neutropenia in pediatric patients with cancer. , 1993, Chemotherapy.

[101]  D. Huhn,et al.  Aerosol amphotericin B for prevention of invasive pulmonary aspergillosis , 1993, Antimicrobial Agents and Chemotherapy.

[102]  G. Mufti,et al.  Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group. , 1993, The Journal of antimicrobial chemotherapy.

[103]  H. Horowitz,et al.  Fluconazole Prophylaxis of Fungal Infections in Patients with Acute Leukemia: Results of a Randomized Placebo-Controlled, Double-Blind, Multicenter Trial , 1993, Annals of Internal Medicine.

[104]  P. Ljungman,et al.  Prophylactic use of liposomal amphotericin B (AmBisome) against fungal infections: a randomized trial in bone marrow transplant recipients. , 1993, Transplantation proceedings.

[105]  J. Raemaekers,et al.  Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. , 1993, Leukemia & lymphoma.

[106]  J. Wout.  Itraconazole in neutropenic patients. , 1992 .

[107]  D. Reece,et al.  Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation. , 1992, Oral surgery, oral medicine, and oral pathology.

[108]  G. Rosner,et al.  Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. , 1992, The Journal of infectious diseases.

[109]  J. Palmblad,et al.  Oral ketoconazole prophylaxis for Candida infections during induction therapy for acute leukaemia in adults: more bacteraemias , 1992, Journal of internal medicine.

[110]  J. L. Goodman,et al.  A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. , 1992, The New England journal of medicine.

[111]  R. Larson,et al.  A pilot study of prophylactic aerosolized amphotericin B in patients at risk for prolonged neutropenia. , 1992, Leukemia & lymphoma.

[112]  A. Prentice,et al.  Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia. , 1991, The Journal of antimicrobial chemotherapy.

[113]  M. Paesmans,et al.  Chemoprophylaxis of Fungal Infections in Granulocytopenic Patients Using Fluconazole vs Oral Amphotericin B , 1991 .

[114]  M. Rinaldi.  Problems in the diagnosis of invasive fungal diseases. , 1991, Reviews of infectious diseases.

[115]  J. Verhoef,et al.  A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukaemia. , 1991, The Journal of antimicrobial chemotherapy.

[116]  C. Noguès,et al.  Does ketoconazole prevent fungal infection in children treated with high dose chemotherapy and bone marrow transplantation? Results of a randomized placebo-controlled trial. , 1991, Bone marrow transplantation.

[117]  G. Schaison,et al.  Prevention of Gram‐positive and Candida albicans infections using teicoplanin and fluconazole: a randomized study in neutropenic children , 1990, British journal of haematology.

[118]  G. Michelone,et al.  Antifungal chemoprophylaxis in cancer children: a prospective randomized controlled study. , 1990, Microbiologica.

[119]  T. Tsubota,et al.  [A co-operative study on prophylactic effect of oral administration of high-dose amphotericin B syrup for systemic fungal infection in patients with hematological neoplasms. Chugoku-Shikoku Study Group of Mycosis with Hematologic Disease]. , 1990, Gan to kagaku ryoho. Cancer & chemotherapy.

[120]  G. Samonis,et al.  Prophylaxis of oropharyngeal candidiasis with fluconazole. , 1990, Reviews of infectious diseases.

[121]  F. Soriano,et al.  Implications of the inoculum effect. , 1990, Reviews of infectious diseases.

[122]  H. Mizoguchi,et al.  Prophylactic and therapeutic effects of oral administration of amphotericin B in mycosis associated with hematologic diseases. Study Group of Mycosis in Hematologic Disease. , 1990, The Japanese journal of antibiotics.

[123]  K. Brammer.  Management of fungal infection in neutropenic patients with fluconazole. , 1990, Haematology and blood transfusion.

[124]  G. Samonis,et al.  Prophylaxis of candidiasis in cancer patients. , 1990, Seminars in oncology.

[125]  A. Prentice,et al.  Prophylaxis of Fungal Infections with Itraconazole during Remission‐Induction Therapy , 1989, Mycoses.

[126]  P. Parikh,et al.  Comparison of clotrimazole with nystatin in preventing oral candidiasis in neutropaenic patients. , 1988, The Indian journal of medical research.

[127]  J. Wingard,et al.  Prevention of fungal sepsis in patients with prolonged neutropenia: a randomized, double-blind, placebo-controlled trial of intravenous miconazole. , 1987, The American journal of medicine.

[128]  R. Abrams,et al.  Ketoconazole in the prevention of candidiasis in patients with cancer. A prospective, randomized, controlled, double-blind study. , 1987, Archives of internal medicine.

[129]  L. G. Malcom,et al.  A randomized trial comparing ketoconazole and nystatin prophylactic therapy in neutropenic patients. , 1987, Cancer investigation.

[130]  E. Bottone,et al.  Clotrimazole treatment for prevention of oral candidiasis in patients with acute leukemia undergoing chemotherapy. Results of a double-blind study. , 1986, The American journal of medicine.

[131]  D. Shepp,et al.  Comparative Trial of Ketoconazole and Nystatin for Prevention of Fungal Infection in Neutropenic Patients Treated in a Protective Environment , 1985 .

[132]  G. Bodey,et al.  Prophylaxis of oropharyngeal candidiasis with clotrimazole. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[133]  J. Anderson,et al.  Ketoconazole prophylaxis in patients with solid tumours receiving aggressive immunosuppressive therapy. An open randomized comparison between 200 mg/d and 400 mg/d doses. , 1985, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[134]  T. Louie,et al.  Nystatin prophylaxis of fungal colonization and infection in granulocytopenic patients: correlation of colonization and clinical outcome. , 1985, Clinical and investigative medicine. Medecine clinique et experimentale.

[135]  R. Quintiliani,et al.  Treatment and prevention of oropharyngeal candidiasis. , 1984, The American journal of medicine.

[136]  R. Fanci,et al.  Fungal infections in hematological neoplastic disease: the possibility of chemoprophylaxis. , 1984, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy.

[137]  E. Estey,et al.  Infection prophylaxis in acute leukemia. Comparative effectiveness of sulfamethoxazole and trimethoprim, ketoconazole, and a combination of the two. , 1984, Archives of internal medicine.

[138]  C. Kauffman,et al.  Effect of Prophylactic Ketoconazole and Nystatin on Fungal Flora , 1984, Mykosen.

[139]  D. Catovsky,et al.  Oral ketoconazole and amphotericin B for the prevention of yeast colonization in patients with acute leukaemia. , 1984, The Journal of hospital infection.

[140]  C. Kauffman,et al.  Efficacy of ketoconazole v nystatin in prevention of fungal infections in neutropenic patients. , 1984, Archives of internal medicine.

[141]  E. Estey,et al.  Infection prophylaxis in acute leukemia , 1984 .

[142]  H. Brincker.  Prevention of Mycosis in Granulocytopenic Patients with Prophylactic Ketoconazole Treatment/Prophylaktische Mykose‐Behandlung mit Ketoconazol bei granulozytopenischen Patienten , 1983, Mykosen.

[143]  J. Klastersky,et al.  Oral prophylaxis with miconazole or ketoconazole of invasive fungal disease in neutropenic cancer patients. , 1983, European journal of cancer & clinical oncology.

[144]  H. Prentice,et al.  KETOCONAZOLE VERSUS NYSTATIN PLUS AMPHOTERICIN B FOR FUNGAL PROPHYLAXIS IN SEVERELY IMMUNOCOMPROMISED PATIENTS , 1982, The Lancet.

[145]  T. Suda,et al.  [A co-operative study on prophylaxis of fungal infection in patients with hematological diseases: prophylactic effect of oral administration of amphotericin B (author's transl)]. , 1980, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[146]  H. Brincker.  Prophylactic treatment with miconazole in patients highly predisposed to fungal infection. A placebo-controlled double-blind study. , 2009, Acta medica Scandinavica.

[147]  T. Lister,et al.  Oral anticandidal prophylaxis in patients undergoing chemotherapy for acut- leukemia. , 1977, Medical and pediatric oncology.